

Insights from the International Center for Cannabis Therapy Part 3:
Reviewing the Many Applications of Cannabinoid-Rich Hemp Oil and the Role of the Gut-Brain Axis
by Chris D. Meletis, ND, and Kimberly Wilkes

References

1. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. *Biol Psychiatry*. 2016 Apr 1;79(7):516-25.
2. Cassano T, et al. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. *Front Neurosci*. 2017 Feb 2;11:30.
3. Benito C, et al. Cannabinoid CB2 receptors in human brain inflammation. *Br J Pharmacol*. 2008 Jan;153(2):277-85.
4. Turcotte C, et al. The CB2 receptor and its role as a regulator of inflammation. *Cell Mol Life Sci*. 2016 Dec;73(23):4449-70.
5. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. *Glia*. 2010 Jul;58(9):1017-30.
6. Onaivi ES, et al. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. *J Psychopharmacol*. 2012 Jan;26(1):92-103.
7. Benito C, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. *J Neurosci*. 2003 Dec 3;23(35):11136-41.
8. Ramírez BG, et al. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci*. 2005 Feb 23;25(8):1904-13.
9. Grünblatt E, et al. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. *J Alzheimers Dis*. 2009;16(3):627-34.
10. Solas M, et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. *Neurobiol Aging*. 2013 Mar;34(3):805-8.
11. Halleskog C, et al. WNT signaling in activated microglia is proinflammatory. *Glia*. 2011 Jan;59(1):119-31.
12. Ehrhart J, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. *Neuroinflammation*. 2005 Dec 12;2:29.
13. Esposito G, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. *Br J Pharmacol*. 2007 Aug;151(8):1272-9.
14. Esposito G, et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARy involvement. *PLoS One*. 2011;6(12):e28668.
15. McGeer PL, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology*. 1988 Aug;38(8):1285-91.
16. Ouchi Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. *Ann Neurol*. 2005 Feb;57(2):168-75.
17. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. *Neurobiol Dis*. 2006 Feb;21(2):404-12.
18. Gómez-Gálvez Y, et al. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016 Jan 4;64:200-8.
19. Chagas MH, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. *J Psychopharmacol*. 2014 Nov;28(11):1088-98.
20. Zuardi AW, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. *J Psychopharmacol*. 2009 Nov;23(8):979-83.
21. Chagas MH, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. *J Clin Pharm Ther*. 2014 Oct;39(5):564-6.
22. Fogaça MV, et al. The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling. *Neuropharmacology*. 2018 Mar 3;135:22-33.
23. Bergamaschi MM, Queiroz RH, Chagas MH. Cannabidiol reduces the anxiety induced by simulated public

- speaking in treatment-naïve social phobia patients. *Neuropsychopharmacology*. 2011 May;36(6):1219-26.
24. Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *J Psychopharmacol*. 2011 Jan;25(1):121-30.
25. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. *Cannabis Cannabinoid Res*. 2016 Jul 1;1(1):154-65.
26. Mizrachi Zer-Aviv T, Segev A, Akirav I. Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. *Behav Pharmacol*. 2016 Oct;27(7):561-9.
27. Jetly R, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology*. 2015 Jan;51:585-8.
28. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? *Behav Pharmacol*. 2005 Sep;16(5-6):333-52.
29. Resstel LB, et al. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. *Br J Pharmacol*. 2009 Jan;156(1):181-8.
30. Granjeiro EM, et al. Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. *Pharmacol Biochem Behav*. 2011 Oct;99(4):743-8.
31. Campos AC, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. *Int J Neuropsychopharmacol*. 2013 Jul;16(6):1407-19.
32. Hill MN, et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. *Pharmacopsychiatry*. 2008 Mar;41(2):48-53.
33. Guida F, et al. Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. *Brain Behav Immun*. 2017 Sep 7. pii: S0889-1591(17)30417-8. [Epub ahead of print.]
34. DiPatrizio NV. Endocannabinoids in the Gut. *Cannabis Cannabinoid Res*. 2016 Feb;1(1):67-77.
35. Alhouayek M, et al. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. *FASEB J*. 2011 Aug;25(8):2711-21.
36. Schicho R, et al. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. *Inflamm Bowel Dis*. 2011 Aug;17(8):1651-64.
37. Borrelli F, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. *J Mol Med (Berl)*. 2009 Nov;87(11):1111-21.
38. De Filippis D, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. *PLoS One*. 2011;6(12):e28159.
39. Darmani NA, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. *Neuropharmacology*. 2005 Jun;48(8):1154-63.
40. Boesmans W, et al. Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. *Neurogastroenterol Motil*. 2009 Sep;21(9):958-e77.
41. Sharkey KA, Wiley JW. The Role of the Endocannabinoid System in the Brain-Gut Axis. *Gastroenterology*. 2016 Aug;151(2):252-66.
42. Marco EM, et al. Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. *Behav Pharmacol*. 2014 Sep;25(5-6):547-56.
43. Moloney RD, et al. Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition. *Neurogastroenterol Motil*. 2015 Dec;27(12):1831-6.
44. Wright K, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. *Gastroenterology*. 2005 Aug;129(2):437-53.
45. Akbar A, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. *Gut*. 2008 Jul;57(7):923-9.
46. Kozela E, et al. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. *J Neuroinflammation*. 2016 Jun 3;13(1):136.
47. Lee WS, et al. Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to

- autoimmunedisorders and organ transplantation. *Mol Med*. 2016 Jan 8. [Epub ahead of print.]
48. Kozela E, et al. Cannabidiol, a non-psych psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells. *J Neuroinflammation*. 2015 Mar 15;12:52.
49. Malfait AM, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis. *Proc Natl Acad Sci U S A*. 2000 Aug 15;97(17):9561-6.
50. Weiss L, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity*. 2006 Mar;39(2):143-51.
51. Hegde VL, Nagarkatti PS, Nagarkatti M. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. *PLoS One*. 2011 Apr 1;6(4):e18281.
52. Weiss L, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology*. 2008 Jan;54(1):244-9.
53. Vaney C, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Mult Scler*. 2004 Aug;10(4):417-24.
54. Leocani L, et al. Sativex(®)and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. *J Neurol*. 2015 Nov;262(11):2520-7.
55. Appendino G, et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. *J Nat Prod*. 2008 Aug;71(8):1427-30.
56. Smith MS, et al. Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila. *Proc Soc Exp Biol Med*. 1997 Jan;214(1):69-75.
57. Hind WH, England TJ, O'Sullivan SE. Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPAR γ and 5-HT1A receptors. *Br J Pharmacol*. 2016 Mar;173(5):815-25.
58. Ceskova E, Silhan P. Novel treatment options in depression and psychosis. *Neuropsychiatr Dis Treat*. 2018;14:741-7.
59. Leweke FM, Mueller JK, Lange B. Therapeutic Potential of Cannabinoids in Psychosis. *Biol Psychiatry*. 2016 Apr 1;79(7):604-12.
60. Warren PP, et al. The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. *Neurocase*. 2017 Oct - Dec;23(5-6):287-91.
61. Kaplan EH, et al. Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. *Pediatr Neurol*. 2017 Jun;71:18-23.e2.
62. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. *Cannabis Cannabinoid Res*. 2017;2(1):139-54.
63. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*. 2014 Jun;55(6):791-802.
64. WebMD. <https://www.webmd.com/vitamins-supplements/ingredientmono-1439-cannabidiol.aspx?activeingredientid=1439&activeingredientname=cannabidiol> Accessed April 3, 2018.
65. Min JY, Min KB. Marijuana use is associated with hypersensitivity to multiple allergens in US adults. *Drug Alcohol Depend*. 2018 Jan 1;182:74-7.
66. Liu DZ, et al. Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity. *Acta Pharmacol Sin*. 2010 Dec;31(12):1611-7.
67. Zhornitsky S, Potvin S. Cannabidiol in Humans—The Quest for Therapeutic Targets. *Pharmaceuticals (Basel)*. 2012 May; 5(5): 529-52.